← Leaderboards
Jason L Vassy
Va Boston Health Care System
$2,747,135
Attributed
$3,197,723
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $855.8K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,197,723 · 2
VA$0 · 3
By mechanism
R35$2,596,939 · 1
U01$600,784 · 1
I01$0 · 2
IK2$0 · 1
Top collaborators
- Marla L. Clayman2 shared
- Lori Ann Orlando1 shared
- Maren Theresa Scheuner1 shared
- Deepak Voora1 shared
Most similar at Va Boston Health Care System
Same institution · by research overlap
- Renda Soylemez Wiener$1,542,263
- Allen L Gifford$2,516,796
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisGenotypeProviderPoint Of CareTreatment As UsualRandomizedHigh RiskScreeningMalignant Neoplasm Of ProstateEnrollmentPolygenic Risk ScorePatient CareLaboratoriesGenetic RiskRecommendationGenetic TestingUsual Care ArmMalignant Breast NeoplasmCostClinical TrialsRandomized Controlled TrialsReportingCaringEvidence Base
Grant awards (18)
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A pragmatic trial of precision prostate cancer screening$0
I01 · FY2025 · VA · contact PI
Building a shared decision making implementation strategy for the emerging paradigm of precision cancer screening$0
I01 · FY2025 · VA
The VA Genomics Learning Health System: Implementing genomic medicine across diverse veteran communities$600,784
U01 · FY2024 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$255,000
R35 · FY2024 · HG · contact PI
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A pragmatic trial of precision prostate cancer screening$0
I01 · FY2024 · VA · contact PI
Building a shared decision making implementation strategy for the emerging paradigm of precision cancer screening$0
I01 · FY2024 · VA
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$494,035
R35 · FY2023 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$90,786
R35 · FY2023 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$388,500
R35 · FY2022 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$386,100
R35 · FY2021 · HG · contact PI
Clinical safety and efficacy of pharmacogenetics in Veteran care$0
IK2 · FY2021 · VA · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$386,100
R35 · FY2020 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$210,318
R35 · FY2020 · HG · contact PI
Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care$386,100
R35 · FY2019 · HG · contact PI
Clinical safety and efficacy of pharmacogenetics in Veteran care$0
IK2 · FY2019 · VA · contact PI
Clinical safety and efficacy of pharmacogenetics in Veteran care$0
IK2 · FY2018 · VA · contact PI
Clinical safety and efficacy of pharmacogenetics in Veteran care$0
IK2 · FY2017 · VA · contact PI
Clinical safety and efficacy of pharmacogenetics in Veteran care$0
IK2 · FY2016 · VA · contact PI